^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DNA polymerase inhibitor

    Related drugs:
    6d
    ANCHORS Alcohol & Sexual Health Study: UH3 Project (clinicaltrials.gov)
    P4, N=88, Recruiting, University of Florida | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    13d
    MIV-818-101: A Study to Evaluate MIV-818 in Patients with Liver Cancer Manifestations (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, Medivir | Trial completion date: Feb 2024 --> Jun 2025 | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • fostroxacitabine bralpamide (MIV-818)
    15d
    VALMCI: Valacyclovir for Mild Cognitive Impairment (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, New York State Psychiatric Institute | Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Nov 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    valacyclovir
    17d
    Vyxeos for Induction of Low- or Intermediate-risk. (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Shaare Zedek Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Mar 2027 --> Sep 2028 | Trial primary completion date: Mar 2024 --> Sep 2028
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    24d
    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM (clinicaltrials.gov)
    P1/2, N=62, Recruiting, The Methodist Hospital Research Institute | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial primary completion date • Gene therapy
    |
    ProstAtak (aglatimagene besadenovec) • valacyclovir
    27d
    Effects of Antiviral Therapies on Epstein-Barr Virus Replication (clinicaltrials.gov)
    P2, N=50, Enrolling by invitation, Massachusetts General Hospital | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    28d
    Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (clinicaltrials.gov)
    P=N/A, N=13, Terminated, University of Alberta | Completed --> Terminated; Protracted gastrointestinal symptoms were experienced by most patients who were subsequently found to be in the treatment arm on LPV/r. This observation resulted in cessation of enrolment and a decision not to continue the RCT
    Trial termination
    1m
    Successful complete remission after induction therapy with CPX-351 for acute myeloid leukemia with myelodysplasia-related changes accompanied by double-minute chromosomes and MYC gene amplification. (PubMed, Int J Hematol)
    No abstract available
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    1m
    VYSION: VYxeoS Liposomal Italian Observational Study iN the Real Practice (clinicaltrials.gov)
    P=N/A, N=112, Active, not recruiting, Jazz Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    1m
    Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics (clinicaltrials.gov)
    P3, N=882, Recruiting, University of Ulm | Trial completion date: Mar 2024 --> Jun 2027 | Trial primary completion date: Mar 2024 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    2ms
    CPX-351 TA-SMP: Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm (clinicaltrials.gov)
    P2, N=42, Completed, French Innovative Leukemia Organisation | Recruiting --> Completed | Trial completion date: Sep 2025 --> Dec 2023
    Trial completion • Trial completion date
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    2ms
    A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Fujifilm Pharmaceuticals U.S.A., Inc. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    liposomal gemcitabine (FF-10832)
    2ms
    Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy. (PubMed, Blood Adv)
    This study highlights that lower-intensity therapy of CPX-351 plus venetoclax as induction therapy provides a well-tolerated treatment option in adults with AML deemed unfit for intensive chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT04038437.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type
    |
    Venclexta (venetoclax) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    2ms
    HPTN 083: Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men (clinicaltrials.gov)
    P2/3, N=4570, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Jul 2024 --> Apr 2025
    Trial completion date
    3ms
    Valacyclovir in Neonatal Herpes Simplex Virus Disease (clinicaltrials.gov)
    P1, N=7, Completed, University of Alabama at Birmingham | Recruiting --> Completed | N=10 --> 7 | Trial completion date: Nov 2025 --> Jul 2024 | Trial primary completion date: Oct 2025 --> Jul 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    valacyclovir
    3ms
    ZEDS: Zoster Eye Disease Study (clinicaltrials.gov)
    P4, N=652, Completed, NYU Langone Health | Active, not recruiting --> Completed
    Trial completion
    |
    valacyclovir
    4ms
    Anti-Inflammatory Immunomodulatory Activity of Valacyclovir on the in Vitro Activated Mammalian Macrophages. (PubMed, Discov Med)
    Valacyclovir has the potential to be utilized in the clinical setting as an anti-viral drug molecule with anti-inflammatory properties. Future studies are needed to further confirm its activities on different immune system cell types.
    Preclinical • Journal • Immunomodulating
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CSF2 (Colony stimulating factor 2)
    |
    valacyclovir
    4ms
    Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1 (clinicaltrials.gov)
    P2, N=54, Recruiting, University of North Carolina, Chapel Hill | Not yet recruiting --> Recruiting
    Enrollment open
    4ms
    CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, University of California, Irvine | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    NPM1 (Nucleophosmin 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation) • Daurismo (glasdegib)
    4ms
    CPX-351 Therapy for MDS After Hypomethylating Agent Failure (clinicaltrials.gov)
    P2, N=4, Terminated, Case Comprehensive Cancer Center | N=25 --> 4 | Recruiting --> Terminated; Slow Accrual
    Enrollment change • Trial termination
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    4ms
    Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes (clinicaltrials.gov)
    P2, N=78, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation) • pomalidomide
    4ms
    The Women TDF-FTC Benchmark Study (clinicaltrials.gov)
    P2, N=72, Active, not recruiting, University of Washington | Trial primary completion date: Mar 2024 --> Jan 2025
    Trial primary completion date
    5ms
    DOXYVAC: Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP) (clinicaltrials.gov)
    P3, N=556, Completed, ANRS, Emerging Infectious Diseases | Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Apr 2024
    Trial completion • Trial completion date
    5ms
    A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer (clinicaltrials.gov)
    P1, N=90, Recruiting, Fujifilm Pharmaceuticals U.S.A., Inc. | Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Sep 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    liposomal gemcitabine (FF-10832)
    5ms
    RTIAGS: Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome (clinicaltrials.gov)
    P1/2, N=34, Not yet recruiting, Children's Hospital of Philadelphia | Trial completion date: Dec 2028 --> Dec 2029 | Trial primary completion date: Dec 2028 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    ADAR (Adenosine Deaminase RNA Specific) • IFIH1 (Interferon Induced With Helicase C Domain 1) • IFNA1 (Interferon Alpha 1)
    5ms
    CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, Case Comprehensive Cancer Center | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    6ms
    Phase IB/II of CPX-351 for Relapse Prevention in AML (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Georgetown University | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    6ms
    Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML (clinicaltrials.gov)
    P1, N=22, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Aug 2025 --> Nov 2025 | Trial primary completion date: Aug 2024 --> Nov 2024
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Xospata (gilteritinib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    6ms
    CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML (clinicaltrials.gov)
    P1, N=18, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Dec 2024 --> Nov 2025
    Trial primary completion date • Combination therapy
    |
    CD33 (CD33 Molecule)
    |
    Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    6ms
    The Kampala Women's Bone Study (clinicaltrials.gov)
    P4, N=500, Completed, University of Washington | Trial completion date: Feb 2022 --> Dec 2023 | Trial primary completion date: Feb 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    6ms
    Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps) (clinicaltrials.gov)
    P3, N=36, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed
    Trial completion • Adherence
    7ms
    Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    CD33 (CD33 Molecule)
    |
    Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    7ms
    Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1 (clinicaltrials.gov)
    P2, N=54, Not yet recruiting, University of North Carolina, Chapel Hill
    New P2 trial
    7ms
    SHIPP: Sustainable Healthcenter Implementation PrEP Pilot Study (clinicaltrials.gov)
    P=N/A, N=1420, Completed, Centers for Disease Control and Prevention | Unknown status --> Completed
    Trial completion
    7ms
    Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=268, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Mar 2027 | Trial primary completion date: Sep 2024 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • Vyxeos (cytarabine/daunorubicin liposomal formulation) • Starasid (cytarabine ocfosfate)
    7ms
    Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2027 --> May 2025 | Trial primary completion date: Feb 2027 --> May 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    7ms
    ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection (clinicaltrials.gov)
    P2, N=32, Completed, Acurx Pharmaceuticals Inc. | Active, not recruiting --> Completed
    Trial completion
    7ms
    Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=18, Recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2024 --> Feb 2027 | Trial primary completion date: May 2024 --> Feb 2027
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD33 (CD33 Molecule)
    |
    CD33 positive
    |
    Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    8ms
    INSIGHT: A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women (clinicaltrials.gov)
    P=N/A, N=3087, Completed, University of Washington | Active, not recruiting --> Completed | Trial completion date: May 2024 --> Aug 2023
    Trial completion • Trial completion date
    8ms
    NCI-2019-03712: Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1/2, N=47, Recruiting, Ohio State University Comprehensive Cancer Center | Suspended --> Recruiting
    Enrollment open • Metastases
    |
    Jakafi (ruxolitinib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    9ms
    ORAZ-351: Oral Azacitidine Maintenance Post-CPX 351 (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Centre Hospitalier Universitaire de Nice
    New trial
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation) • Onureg (azacitidine oral)
    9ms
    Antiviral: Valacyclovir Monotherapy in Pain Management of Acute Periapical Abscesses After Emergency Chamber Opening (clinicaltrials.gov)
    P4, N=82, Recruiting, Dow University of Health Sciences
    New P4 trial
    |
    valacyclovir